- Home
- PSNL vs EYPT Comparison
PSNL vs EYPT Comparison
Compare PSNL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- EYPT
- Stock Information
- Founded
- PSNL 2011
- EYPT 1987
- Country
- PSNL United States
- EYPT United States
- Employees
- PSNL N/A
- EYPT N/A
- Industry
- PSNL Medical Specialities
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- PSNL Health Care
- EYPT Industrials
- Exchange
- PSNL Nasdaq
- EYPT Nasdaq
- Market Cap
- PSNL 415.1M
- EYPT 484.4M
- IPO Year
- PSNL 2019
- EYPT 2005
- Fundamental
- Price
- PSNL $5.30
- EYPT $8.92
- Analyst Decision
- PSNL Strong Buy
- EYPT Strong Buy
- Analyst Count
- PSNL 5
- EYPT 8
- Target Price
- PSNL $8.00
- EYPT $24.29
- AVG Volume (30 Days)
- PSNL 656.8K
- EYPT 895.1K
- Earning Date
- PSNL 05-06-2025
- EYPT 05-07-2025
- Dividend Yield
- PSNL N/A
- EYPT N/A
- EPS Growth
- PSNL N/A
- EYPT N/A
- EPS
- PSNL N/A
- EYPT N/A
- Revenue
- PSNL $85,694,000.00
- EYPT $56,042,000.00
- Revenue This Year
- PSNL $0.45
- EYPT N/A
- Revenue Next Year
- PSNL $25.75
- EYPT N/A
- P/E Ratio
- PSNL N/A
- EYPT N/A
- Revenue Growth
- PSNL 15.57
- EYPT 12.04
- 52 Week Low
- PSNL $1.14
- EYPT $3.91
- 52 Week High
- PSNL $7.20
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- PSNL 66.92
- EYPT 74.02
- Support Level
- PSNL $4.47
- EYPT $7.98
- Resistance Level
- PSNL $5.39
- EYPT $8.36
- Average True Range (ATR)
- PSNL 0.31
- EYPT 0.55
- MACD
- PSNL 0.01
- EYPT 0.24
- Stochastic Oscillator
- PSNL 93.64
- EYPT 96.39
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.